SLXN
HEALTHCARESilexion Therapeutics Corp
$0.57-0.03 (-5.09%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SLXN Today?
No stock-specific AI insight has been generated for SLXN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.47$22.36
$0.57
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-8.96
Dividend Yield—
Dividend / Share—
ROE-7.7%
Profit Margin—
Debt / Equity—
Trading
Volume70K
Avg Volume (10D)—
Shares Outstanding4.1M
SLXN News
20 articles- Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic CancerYahoo Finance·Apr 28, 2026
- Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerYahoo Finance·Mar 24, 2026
- Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 17, 2026
- Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General MeetingYahoo Finance·Mar 5, 2026
- Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics SummitYahoo Finance·Jan 21, 2026
- Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026Yahoo Finance·Jan 6, 2026
- Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic CancerYahoo Finance·Dec 16, 2025
- Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic CancerYahoo Finance·Dec 2, 2025
- Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity ConferenceYahoo Finance·Nov 26, 2025
- Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic CancerYahoo Finance·Nov 25, 2025
- Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 12, 2025
- Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric CancerYahoo Finance·Sep 30, 2025
- Silexion Therapeutics Regains Compliance with Nasdaq Listing RequirementsYahoo Finance·Sep 25, 2025
- Silexion Therapeutics Announces Pricing of $6.0 Million Public OfferingYahoo Finance·Sep 11, 2025
- Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationYahoo Finance·Sep 11, 2025
- Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204Yahoo Finance·Sep 4, 2025
- Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceYahoo Finance·Sep 2, 2025
- Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 12, 2025
- Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsYahoo Finance·Aug 1, 2025
- Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationYahoo Finance·Jul 31, 2025
All 20 articles loaded
Price Data
Open$0.63
Previous Close$0.60
Day High$0.64
Day Low$0.59
52 Week High$22.36
52 Week Low$0.47
52-Week Range
$0.47$22.36
$0.57
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-8.96
Dividend Yield—
Dividend / Share—
ROE-7.7%
Profit Margin—
Debt / Equity—
Trading
Volume70K
Avg Volume (10D)—
Shares Outstanding4.1M
About Silexion Therapeutics Corp
Biomotion Sciences (SLXN) is an innovative biotechnology firm specializing in regenerative medicine, dedicated to developing transformative therapies for severe and complex medical conditions. With a robust pipeline of promising product candidates, the company aims to significantly enhance patient outcomes and address unmet medical needs. Supported by strategic collaborations that bolster its research and development capabilities, Biomotion Sciences is well-positioned to thrive in the rapidly evolving biotechnology landscape, presenting a compelling investment opportunity for institutional investors seeking exposure to cutting-edge therapeutics.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—